Comparison of DPP-4 inhibitor, sitagliptin and nateglinide, and liraglutide and exenatide in type 2 diabetes: a CGM based-study
Not Applicable
- Conditions
- Type 2 diabetes mellitus
- Registration Number
- JPRN-UMIN000006799
- Lead Sponsor
- Yokohama City University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
Not provided
Exclusion Criteria
1)severe ketosis, diabetic coma within 6 months 2)severe infection, before operation, severe trauma 3)severe hepatic dysfunction 4)or severe renal dysfunction (eGFR: more than 1.5mg/dl) 5)Patients who use of insulin 6)pregnacy 7)Allergy for sitagliptin, nateglinide,liraglutide and exenatide 8)Patients judged by the investigator to be ineligible for some other reason
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Standard deviation of blood glucose by CGM
- Secondary Outcome Measures
Name Time Method 1)averate blood glucose, MAGE by CGM 2)FPG and PPG at 1, 2, 3, 4, 5, 6, 7 days of treatment 3)%chagne of FPG, HbA1c,IRI,CPR, a from baseline